Boehringer Ingelheim Corporation Release: Nintedanib* Receives Positive CHMP Opinion For Second-Line Treatment Of Patients With Adenocarcinoma Of The Lung

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of nintedanib* (suggested brand name Vargatef®) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Help employers find you! Check out all the jobs and post your resume.